Respiratory Distress Syndrome Clinical Trial
Official title:
A Randomized, Controlled, Partially Double-blinded, Phase 3, Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 31+6 Weeks Gestational Age
The purpose of this study is to see if a medication called Curosurf can reduce the length of
time that small premature babies with Respiratory Distress Syndrome (immature lungs) or RDS,
stay on the ventilator, as compared to the standard medication called BLES. Curosurf is a
medication that is already used in other countries around the world but not yet in Canada.
Babies born under 32 weeks of gestation frequently need respiratory support after birth,
including being placed on a breathing machine or respirator. The most common reason is
Respiratory Distress Syndrome (RDS) whereby immature lungs don't produce enough surfactant, a
soapy like substance that helps the air sacs open and close. Our current standard treatment
is a surfactant called BLES. Curosurf contains more active ingredient per volume therefore
the amount is smaller. The investigators hypothesize that babies who receive Curosurf will be
able to be removed from the ventilator sooner.
Babies in this study will have a 50/50 chance of receiving either Curosurf or BLES and the
investigators will monitor their progress during their Neonatal Intensive Care Unit
admission.
The study is taking place in Canada. The goal is to enroll 88 babies. There are no extra
tests (blood tests or X-Rays) or return visits to the hospital for the purposes of this
study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06168149 -
The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
|
||
Recruiting |
NCT03670732 -
CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure
|
N/A | |
Recruiting |
NCT02901652 -
NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Suspended |
NCT01852916 -
NHFOV Versus NCPAP to Prevent Exubation Failure
|
N/A | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Recruiting |
NCT03510169 -
Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe
|
N/A | |
Completed |
NCT00004494 -
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
|
Phase 1 | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT03292562 -
A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation
|
N/A | |
Completed |
NCT05948332 -
Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
|
||
Completed |
NCT05038514 -
The Effect of Music Therapy in COVID-19 Patients Given Prone Position
|
N/A | |
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Completed |
NCT05462509 -
Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda
|
N/A | |
Active, not recruiting |
NCT03808402 -
The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
|
||
Completed |
NCT01812681 -
Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities
|
N/A | |
Completed |
NCT01517958 -
Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates
|
N/A | |
Not yet recruiting |
NCT01440868 -
Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01222247 -
Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
|
Phase 3 |